BBlogFlow

How good is this year's flu shot? Here's what to know about flu season - CBC

·Oct 9, 2026

This story deserves to be shared

Send it to someone who'd care, or post it on your networks.

Facebook Twitter Email

Walking down the street this week, it may seem like everyone is sneezing and hacking up a lung. But as health officials announce the start of an earlier than usual flu season, how worried should Canadians be? And as we head into Thanksgiving weekend, should we be scrambling to update flu and COVID-19 shots? Some experts say that while this year's flu season may have arrived on our doorstep sooner than usual, it's not necessarily a cause for alarm — but other experts are stressing the importance of prevention in heavy-hit regions such as Toronto and Calgary, where one of this season's two influenza deaths so far has occurred, according to authorities. The strain making up roughly 98 per cent of cases in Canada so far tends to be a milder one, according to Brian Ward, professor emeritus at the Research Institute of the McGill University Health Centre in Montreal. "So far at least, this looks like an H1N1 dominated year, and the years where H1N1 dominates, you can have very large outbreaks, but the number or the proportion of people … who get very sick, is relatively small compared to years that are dominated by H3N2," he told CBC News.

This article is an excerpt. To read the full content, visit the original source. CBC

Reactions

0 comments

No comments yet. Be the first to share your thoughts!

Facebook Twitter

Related articles

Continuous glucose monitors help type 2 diabetes patients spend 5 more hours a day in healthy blood sugar range - Medical Xpress

Continuous glucose monitors (CGMs) could transform diabetes management for millions of Americans with type 2 diabetes who don't take insulin, according to findings published in the New England Journal of Medicine. The clinical trial found that adults using CGMs spent approximately five additional hours each day within their target blood sugar range compared with those receiving routine care. Nearly twice as many CGM users also achieved an A1c level below 7%, a common treatment goal for people with diabetes.

Medical Xpress·

Kefah Mokbel: Can Whole-Genome Sequencing-Based ctDNA Monitoring Help Personalize Adjuvant Treatment? - Oncodaily

“Beyond Detecting Cancer Recurrence: Can Whole-Genome Sequencing-Based ctDNA Monitoring Help Personalize Adjuvant Treatment? An exciting new study published in The Oncologist highlights the clinical potential of Signatera Genome, a whole-genome sequencing (WGS)-based, tumor-informed circulating tumor DNA (ctDNA) assay, not only for detecting molecular residual disease (MRD), but also for potentially informing adjuvant treatment decisions.

Oncodaily·